Logo image of ARWR

ARROWHEAD PHARMACEUTICALS IN (ARWR) Stock Fundamental Analysis

NASDAQ:ARWR - Nasdaq - US04280A1007 - Common Stock - Currency: USD

15.74  -0.48 (-2.96%)

After market: 15.5169 -0.22 (-1.42%)

Fundamental Rating

3

Taking everything into account, ARWR scores 3 out of 10 in our fundamental rating. ARWR was compared to 559 industry peers in the Biotechnology industry. The financial health of ARWR is average, but there are quite some concerns on its profitability. ARWR is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

ARWR had negative earnings in the past year.
In the past year ARWR had a positive cash flow from operations.
ARWR had negative earnings in each of the past 5 years.
In the past 5 years ARWR reported 4 times negative operating cash flow.
ARWR Yearly Net Income VS EBIT VS OCF VS FCFARWR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200M -400M -600M

1.2 Ratios

With an excellent Return On Assets value of -9.15%, ARWR belongs to the best of the industry, outperforming 84.79% of the companies in the same industry.
ARWR's Return On Equity of -21.07% is amongst the best of the industry. ARWR outperforms 84.97% of its industry peers.
Industry RankSector Rank
ROA -9.15%
ROE -21.07%
ROIC N/A
ROA(3y)-34.95%
ROA(5y)-28.18%
ROE(3y)-147.71%
ROE(5y)-99.18%
ROIC(3y)N/A
ROIC(5y)N/A
ARWR Yearly ROA, ROE, ROICARWR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ARWR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARWR Yearly Profit, Operating, Gross MarginsARWR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

More info and screens

5

2. Health

2.1 Basic Checks

ARWR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ARWR has been increased compared to 1 year ago.
ARWR has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ARWR has a worse debt to assets ratio.
ARWR Yearly Shares OutstandingARWR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ARWR Yearly Total Debt VS Total AssetsARWR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of 1.03, we must say that ARWR is in the distress zone and has some risk of bankruptcy.
ARWR has a better Altman-Z score (1.03) than 66.73% of its industry peers.
ARWR has a debt to FCF ratio of 28.55. This is a negative value and a sign of low solvency as ARWR would need 28.55 years to pay back of all of its debts.
ARWR's Debt to FCF ratio of 28.55 is amongst the best of the industry. ARWR outperforms 91.06% of its industry peers.
A Debt/Equity ratio of 0.31 indicates that ARWR is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.31, ARWR is not doing good in the industry: 72.27% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF 28.55
Altman-Z 1.03
ROIC/WACCN/A
WACC9.38%
ARWR Yearly LT Debt VS Equity VS FCFARWR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M -600M

2.3 Liquidity

ARWR has a Current Ratio of 5.15. This indicates that ARWR is financially healthy and has no problem in meeting its short term obligations.
ARWR has a Current ratio of 5.15. This is comparable to the rest of the industry: ARWR outperforms 54.02% of its industry peers.
ARWR has a Quick Ratio of 5.15. This indicates that ARWR is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 5.15, ARWR is in line with its industry, outperforming 55.10% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.15
Quick Ratio 5.15
ARWR Yearly Current Assets VS Current LiabilitesARWR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 67.22% over the past year.
The Revenue has grown by 1438.05% in the past year. This is a very strong growth!
The Revenue for ARWR have been decreasing by -53.80% on average. This is quite bad
EPS 1Y (TTM)67.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%369.61%
Revenue 1Y (TTM)1438.05%
Revenue growth 3Y-70.5%
Revenue growth 5Y-53.8%
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 14.82% on average over the next years. This is quite good.
Based on estimates for the next years, ARWR will show a very strong growth in Revenue. The Revenue will grow by 62.19% on average per year.
EPS Next Y43.48%
EPS Next 2Y13.24%
EPS Next 3Y5.25%
EPS Next 5Y14.82%
Revenue Next Year923.26%
Revenue Next 2Y107.18%
Revenue Next 3Y72.15%
Revenue Next 5Y62.19%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ARWR Yearly Revenue VS EstimatesARWR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B 2.5B
ARWR Yearly EPS VS EstimatesARWR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 10 15

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ARWR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ARWR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ARWR Price Earnings VS Forward Price EarningsARWR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

ARWR's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ARWR is cheaper than 91.06% of the companies in the same industry.
Industry RankSector Rank
P/FCF 226.52
EV/EBITDA N/A
ARWR Per share dataARWR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.24%
EPS Next 3Y5.25%

More info and screens

0

5. Dividend

5.1 Amount

ARWR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARROWHEAD PHARMACEUTICALS IN

NASDAQ:ARWR (6/13/2025, 8:00:01 PM)

After market: 15.5169 -0.22 (-1.42%)

15.74

-0.48 (-2.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-06 2025-08-06/amc
Inst Owners81.34%
Inst Owner Change4.28%
Ins Owners4.43%
Ins Owner Change6.82%
Market Cap2.17B
Analysts78.1
Price Target45.39 (188.37%)
Short Float %11.03%
Short Ratio6.74
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)625.15%
Min EPS beat(2)-211.36%
Max EPS beat(2)1461.66%
EPS beat(4)1
Avg EPS beat(4)269.22%
Min EPS beat(4)-211.36%
Max EPS beat(4)1461.66%
EPS beat(8)1
Avg EPS beat(8)50.38%
EPS beat(12)2
Avg EPS beat(12)-2.29%
EPS beat(16)3
Avg EPS beat(16)1.62%
Revenue beat(2)1
Avg Revenue beat(2)791.73%
Min Revenue beat(2)-96.63%
Max Revenue beat(2)1680.09%
Revenue beat(4)1
Avg Revenue beat(4)345.87%
Min Revenue beat(4)-100%
Max Revenue beat(4)1680.09%
Revenue beat(8)1
Avg Revenue beat(8)132.24%
Revenue beat(12)2
Avg Revenue beat(12)94.15%
Revenue beat(16)4
Avg Revenue beat(16)69.08%
PT rev (1m)-0.09%
PT rev (3m)-2.81%
EPS NQ rev (1m)-13.03%
EPS NQ rev (3m)-5.59%
EPS NY rev (1m)23.69%
EPS NY rev (3m)26.84%
Revenue NQ rev (1m)-47.98%
Revenue NQ rev (3m)-47.98%
Revenue NY rev (1m)391.57%
Revenue NY rev (3m)391.57%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.99
P/FCF 226.52
P/OCF 35.55
P/B 3.18
P/tB 3.22
EV/EBITDA N/A
EPS(TTM)-1.39
EYN/A
EPS(NY)-3.6
Fwd EYN/A
FCF(TTM)0.07
FCFY0.44%
OCF(TTM)0.44
OCFY2.81%
SpS3.95
BVpS4.95
TBVpS4.89
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -9.15%
ROE -21.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 1.76%
ROA(3y)-34.95%
ROA(5y)-28.18%
ROE(3y)-147.71%
ROE(5y)-99.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF 28.55
Debt/EBITDA N/A
Cap/Depr 244.02%
Cap/Sales 9.46%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.15
Quick Ratio 5.15
Altman-Z 1.03
F-Score5
WACC9.38%
ROIC/WACCN/A
Cap/Depr(3y)894.03%
Cap/Depr(5y)633.96%
Cap/Sales(3y)1359.68%
Cap/Sales(5y)821.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)67.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%369.61%
EPS Next Y43.48%
EPS Next 2Y13.24%
EPS Next 3Y5.25%
EPS Next 5Y14.82%
Revenue 1Y (TTM)1438.05%
Revenue growth 3Y-70.5%
Revenue growth 5Y-53.8%
Sales Q2Q%N/A
Revenue Next Year923.26%
Revenue Next 2Y107.18%
Revenue Next 3Y72.15%
Revenue Next 5Y62.19%
EBIT growth 1Y74.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year76.15%
EBIT Next 3Y-0.59%
EBIT Next 5Y11.01%
FCF growth 1Y102.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y124.99%
OCF growth 3YN/A
OCF growth 5YN/A